-$1.73 EPS Expected for Ultragenyx Pharmaceutical Inc. (RARE) This Quarter

Equities analysts predict that Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) will report earnings per share of ($1.73) for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for Ultragenyx Pharmaceutical’s earnings. The highest EPS estimate is ($1.59) and the lowest is ($1.83). Ultragenyx Pharmaceutical posted earnings per share of ($1.46) during the same quarter last year, which would indicate a negative year over year growth rate of 18.5%. The firm is scheduled to announce its next quarterly earnings report on Monday, August 14th.

On average, analysts expect that Ultragenyx Pharmaceutical will report full-year earnings of ($7.04) per share for the current year, with EPS estimates ranging from ($7.80) to ($6.52). For the next fiscal year, analysts expect that the firm will report earnings of ($6.52) per share, with EPS estimates ranging from ($7.83) to ($5.22). Zacks’ earnings per share calculations are an average based on a survey of research firms that follow Ultragenyx Pharmaceutical.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings data on Thursday, May 4th. The biopharmaceutical company reported ($1.63) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.71) by $0.08. During the same quarter last year, the firm earned ($1.35) EPS.

A number of equities research analysts recently weighed in on RARE shares. Piper Jaffray Companies reaffirmed a “neutral” rating on shares of Ultragenyx Pharmaceutical in a research note on Thursday, March 23rd. HC Wainwright downgraded shares of Ultragenyx Pharmaceutical from a “buy” rating to a “neutral” rating and lowered their target price for the company from $88.00 to $72.00 in a research note on Wednesday, April 19th. Jefferies Group LLC raised their target price on shares of Ultragenyx Pharmaceutical from $66.00 to $68.00 and gave the company a “hold” rating in a research note on Monday, May 8th. SunTrust Banks, Inc. raised their target price on shares of Ultragenyx Pharmaceutical from $100.00 to $105.00 and gave the company a “buy” rating in a research note on Wednesday, April 19th. Finally, Wedbush downgraded shares of Ultragenyx Pharmaceutical from an “outperform” rating to a “neutral” rating and decreased their price target for the stock from $80.00 to $75.00 in a research note on Wednesday, April 19th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and eight have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $82.93.

In other news, VP Theodore Alan Huizenga sold 480 shares of the firm’s stock in a transaction that occurred on Friday, May 26th. The shares were sold at an average price of $57.46, for a total value of $27,580.80. Following the transaction, the vice president now owns 9,366 shares in the company, valued at $538,170.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 10.10% of the stock is currently owned by company insiders.

Several hedge funds and other institutional investors have recently modified their holdings of RARE. FMR LLC boosted its position in shares of Ultragenyx Pharmaceutical by 3.9% in the first quarter. FMR LLC now owns 6,110,627 shares of the biopharmaceutical company’s stock valued at $414,178,000 after buying an additional 227,802 shares in the last quarter. BlackRock Inc. boosted its position in shares of Ultragenyx Pharmaceutical by 102,249.1% in the first quarter. BlackRock Inc. now owns 3,166,680 shares of the biopharmaceutical company’s stock valued at $214,637,000 after buying an additional 3,163,586 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Ultragenyx Pharmaceutical by 5.7% in the first quarter. Vanguard Group Inc. now owns 2,994,938 shares of the biopharmaceutical company’s stock valued at $202,997,000 after buying an additional 161,622 shares in the last quarter. Columbia Wanger Asset Management LLC boosted its position in shares of Ultragenyx Pharmaceutical by 5.3% in the first quarter. Columbia Wanger Asset Management LLC now owns 1,237,825 shares of the biopharmaceutical company’s stock valued at $83,900,000 after buying an additional 62,209 shares in the last quarter. Finally, Capital Guardian Trust Co. boosted its position in shares of Ultragenyx Pharmaceutical by 15.7% in the fourth quarter. Capital Guardian Trust Co. now owns 570,321 shares of the biopharmaceutical company’s stock valued at $40,099,000 after buying an additional 77,421 shares in the last quarter. Hedge funds and other institutional investors own 95.38% of the company’s stock.

Ultragenyx Pharmaceutical (NASDAQ:RARE) traded up 1.16% during trading on Tuesday, reaching $66.42. 539,473 shares of the company were exchanged. The firm’s 50-day moving average is $58.65 and its 200 day moving average is $68.96. Ultragenyx Pharmaceutical has a one year low of $46.52 and a one year high of $91.35. The company’s market capitalization is $2.81 billion.

COPYRIGHT VIOLATION WARNING: “-$1.73 EPS Expected for Ultragenyx Pharmaceutical Inc. (RARE) This Quarter” was originally posted by Mideast Time and is the property of of Mideast Time. If you are reading this article on another domain, it was illegally copied and republished in violation of United States and international copyright law. The legal version of this article can be accessed at https://www.mideasttime.com/1-73-eps-expected-for-ultragenyx-pharmaceutical-inc-rare-this-quarter/1809840.html.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:RARE”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Get a free copy of the Zacks research report on Ultragenyx Pharmaceutical (RARE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.